药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Glucosamine
Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated)
The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Ponatinib.
Glucosamine
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ponatinib.
Glucosamine
Clostridium tetani toxoid antigen (formaldehyde inactivated)
The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ponatinib.
Glucosamine
Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen
The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Ponatinib.
Glucosamine
Rabies virus inactivated antigen, A
The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Ponatinib.
Glucosamine
Rotavirus vaccine
The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Ponatinib.
Glucosamine
Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen
The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Ponatinib.
Glucosamine
Rabies virus inactivated antigen, B
The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Ponatinib.
Glucosamine
Anthrax immune globulin human
The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Ponatinib.
Glucosamine
TG4010
The therapeutic efficacy of TG4010 can be decreased when used in combination with Ponatinib.
Glucosamine
Vitespen
The therapeutic efficacy of Vitespen can be decreased when used in combination with Ponatinib.
Glucosamine
GI-5005
The therapeutic efficacy of GI-5005 can be decreased when used in combination with Ponatinib.
Glucosamine
SRP 299
The therapeutic efficacy of SRP 299 can be decreased when used in combination with Ponatinib.
Glucosamine
Rindopepimut
The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Ponatinib.
Glucosamine
INGN 225
The therapeutic efficacy of INGN 225 can be decreased when used in combination with Ponatinib.
Glucosamine
PEV3A
The therapeutic efficacy of PEV3A can be decreased when used in combination with Ponatinib.
Glucosamine
G17DT
The therapeutic efficacy of G17DT can be decreased when used in combination with Ponatinib.
Glucosamine
Lorcaserin
The metabolism of Ponatinib can be decreased when combined with Lorcaserin.
Glucosamine
Dosulepin
The metabolism of Dosulepin can be decreased when combined with Ponatinib.
Glucosamine
Lumefantrine
The metabolism of Ponatinib can be decreased when combined with Lumefantrine.